0
Startups & Venture·September 22, 2026·1 min read

Biolevate raises €30M Series A and opens Boston office for its life sciences AI

Share

€30M into Biolevate’s AI automation for regulated life sciences — plus a Boston beachhead — is another data point that pharma and medtech workflows are becoming software-first. If you operate in GxP environments, expect buyers and regulators to normalize AI-driven automation and start budgeting for validated, audit-friendly tooling.